Costco Wholesale Corporation vs Sana Biotechnology Inc — how do they compare? Costco Wholesale Corporation trades at $948.89 (market cap $418.79B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Costco Wholesale Corporation is far larger — about 370.6× Sana Biotechnology Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| COST | SANA | |
|---|---|---|
Market Cap | $418.79B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $5.92 |
52-Week Low | $849.63 | $2.68 |
Enterprise Value | $406.93B | $1.05B |
Dividend Yield | 0.62% | — |
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $948.43, down 0.45% on the day, with technical indicators signaling a bearish trend amid neutral oscillators. The stock shows strong fundamentals with revenue growth to $275.24 billion in 2025 and consistent earnings beats, though it missed Q1 2026 estimates. Recent news highlights membership fee hikes and robust March sales, while analyst consensus remains bullish with a $1,120 price target.
The outlook for COST is positive due to steady revenue growth and high analyst confidence, but risks include elevated valuation multiples and competitive pressures. Investment opportunity lies in its scalable business model and membership-driven profits, though investors should monitor earnings consistency and macroeconomic impacts on consumer spending.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Trailing returns across standard periods
Latest headlines on both assets
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →